Mirror life, a concept involving synthetic organisms with reversed molecular structures, carries significant risks despite its potential for medical advancements.
Experts warn that mirror bacteria could escape natural biological controls, potentially evolving to exploit resources in ways that disrupt ecosystems and pose unforeseen dangers to the environment and public health.
Mirror Life
Tires and degrading garbage shed tiny pieces of plastic into the air, creating a form of air pollution that UC San Francisco researchers suspect may be causing respiratory and other illnesses.
A review of some 3,000 studies implicates these particles in a variety of serious health problems. These include male and female infertility, colon cancer and poor lung function. The particles also may contribute to chronic pulmonary inflammation, which can increase the risk of lung cancer.
“These microplastics are basically particulate matter air pollution, and we know this type of air pollution is harmful,” said Tracey J. Woodruff, Ph.D., MPH, a professor of obstetrics, gynecology and reproductive sciences at UCSF.
face_with_colon_three A gasoline free future could be used for flying vehicles like cars, spaceships, homes, citywide generators, and really shows a kinda Star Trek and alien like future utopian world free of cancerous gases. It could make the world really clean and it would be perfect for spaceships.
This study reports the creation of a model thermodynamic engine that is fuelled by the energy difference resulting from changing the statistics of a quantum gas from bosonic to fermionic.
Lung cancer is the major cause of cancer death worldwide. Cancer immunotherapy has been introduced as a promising and effective treatment that can improve the immune system’s ability to eliminate cancer cells and help establish immunological memory. Nanoparticles can contribute to the rapidly evolving field of immunotherapy by simultaneously delivering a variety of immunological agents to the target site and tumor microenvironment. Nano drug delivery systems can precisely target biological pathways and be implemented to reprogram or regulate immune responses. Numerous investigations have been conducted to employ different types of nanoparticles for immunotherapy of lung cancer. Nano-based immunotherapy adds a strong tool to the diverse collection of cancer therapies. This review briefly summarizes the remarkable potential opportunities for nanoparticles in lung cancer immunotherapy and its challenges.
Humankind’s quest to defeat cancer continues by developing targeted treatments. Among the frequently used cancer treatments with significant improvements are chemotherapy, radiation therapy, surgery, and combinations of them. However, these strategies have various limitations; for instance, although surgery offers the best outcome for cancers detected at early stages, this approach often falls short for cancers detected at late stages which have already spread throughout the body. Furthermore, chemotherapy has low specificity, drug-induced side effects, and drug resistance, and has shown higher cancer relapse rates similar to radiation therapy (Velpurisiva et al., 2017; Doroudian et al., 2020; Niloy et al., 2021; Anconina et al., 2022; Hosseinkazemi et al., 2022). As a result, researchers were encouraged to make use of the human body’s own defense system as a tool to fight cancer.
Immunotherapy boosts a person’s own immune system to identify and fight cancer cells that normally evade its defenses.
However, like traditional cancer treatments, immunotherapy may cause or exacerbate cognitive decline, especially in older adults. Because this treatment is much newer than chemotherapy or radiation, these potential side effects have not yet been widely studied.
Gee Su Yang, assistant professor at the UConn School of Nursing, has received a $60,000 CRISP (Clinical Research Innovation Seed Program) Award from the Office of the Vice President for Research to conduct a pilot study of how immunotherapy impacts cognitive function in older cancer patients.
Empa researchers are working on artificial muscles that can keep up with the real thing. They have now developed a method of producing the soft and elastic, yet powerful structures using 3D printing. One day, these could be used in medicine or robotics – and anywhere else where things need to move at the touch of a button.
A team of researchers from Empa’s Laboratory for Functional Polymers is working on actuators made of soft materials. Now, for the first time, they have developed a method for producing such complex components using a 3D printer. The so-called dielectric elastic actuators (DEA) consist of two different silicone-based materials: a conductive electrode material and a non-conductive dielectric. These materials interlock in layers. “It’s a bit like interlacing your fingers,” explains Empa researcher Patrick Danner. If an electrical voltage is applied to the electrodes, the actuator contracts like a muscle. When the voltage is switched off, it relaxes to its original position.
3D printing such a structure is not trivial, Danner knows. Despite their very different electrical properties, the two soft materials should behave very similarly during the printing process. They should not mix but must still hold together in the finished actuator. The printed “muscles” must be as soft as possible so that an electrical stimulus can cause the required deformation. Added to this are the requirements that all 3D printable materials must fulfill: They must liquefy under pressure so that they can be extruded out of the printer nozzle. Immediately thereafter, however, they should be viscous enough to retain the printed shape. “These properties are often in direct contradiction,” says Danner. “If you optimize one of them, three others change … usually for the worse.”
Did you know that up to 20% of people with lung cancer have never smoked?
Sherlock-Lung is a comprehensive study that uses genomic approaches to trace the causes of lung cancer among people who have never smoked.
Sherlock Lung is a genomic epidemiologic study of lung cancer in never smokers conducted by researchers in DCEG.
Histone proteins provide essential structural support for DNA in chromosomes, acting as spools around which DNA strands wrap. These proteins have been well studied, but most current tools to study gene expression rely on RNA sequencing. Histone RNA is unique in that its structure prevents the RNA molecules from being detected by current methods.
Thus, the expression of histone genes may be significantly underestimated in tumor samples. The researchers hypothesized that the increased proliferation of cancer cells leads to a very elevated expression, or hypertranscription, of histones to meet the added demands of cell replication and division.
To test their hypothesis, the researchers used CUTAC profiling to examine and map RNAPII, which transcribes DNA into precursors of messenger RNA. They studied 36 FFPE samples from patients with meningioma – a common and benign brain tumor – and used a novel computational approach to integrate this data with nearly 1,300 publicly available clinical data samples and corresponding clinical outcomes.
In tumor samples, the RNAPII enzyme signals found on histone genes were reliably able to distinguish between cancer and normal samples.
RNAPII signals on histone genes also correlated with clinical grades in meningiomas, accurately predicting rapid recurrence as well as the tendency of whole-arm chromosome losses. Using this technology on breast tumor FFPE samples from 13 patients with invasive breast cancer also predicted cancer aggressiveness.
Using a new technology and computational method, researchers have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers.
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic proteins that can help treat or prevent disease by replacing missing proteins, reducing harmful ones, or activating the body’s defenses.
The research team designed and tested a library of lipids to optimize their ability to cross the blood-brain barrier. Through a series of structural and functional analyses, they identified a lead formulation, termed MK16 BLNP, that exhibited significantly higher mRNA delivery efficiency than existing lipid nanoparticles approved by the Food and Drug Administration (FDA). This system takes advantage of natural transport mechanisms within the blood-brain barrier, including caveolae-and γ-secretase-mediated transcytosis, to move nanoparticles across the barrier, say the investigators.
In studies using mouse models of disease, the BLNP platform successfully delivered therapeutic mRNAs to the brain, demonstrating its potential for clinical application.
Scientists have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective nature of the blood-brain barrier.
The findings, in mouse models and isolated human brain tissue, were published in Nature Materials. They demonstrate the potential of this technology to pave the way for future treatments for a wide range of conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, brain cancer, and drug addiction.
The blood-brain barrier serves as a protective shield, preventing many substances—including potentially beneficial therapies—from reaching the brain. While previous research introduced a platform for transporting large biomolecules such as proteins and oligonucleotides into the central nervous system, this new study focuses on a different approach: using specially designed lipid nanoparticles to transport mRNA across the barrier.